Meeting
2018 ASCO Annual Meeting
STATEC: A randomised trial of non-selective versus selective adjuvant therapy in high risk apparent stage 1 endometrial cancer.
Authors
Tim Mould
University College London Hospital, London, United Kingdom
Tim Mould , Alison Brand , Hans Nijman , Jonathan A. Ledermann , Richard J Edmondson , Jeremy Twigg , Emma Hudson , Carien L. Creutzberg , Naveena Singh , Raji Ganesan , Amanda Feeney , Laura Farrelly , Laura Hughes , Allan Hackshaw , Abigail Sharp , Peey Sei Kok , Henry C. Kitchener
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Uterine Cancer
Clinical Trial Registration Number
NCT02566811
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS5615)
DOI
10.1200/JCO.2018.36.15_suppl.TPS5615
Abstract #
TPS5615
Poster Bd #
334b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
CCTG EN10: A phase II study of tailored adjuvant therapy in POLE-mutated and p53-wildtype/NSMP early-stage endometrial cancer (EC)—RAINBO BLUE and TAPER.
First Author: Jessica N. McAlpine
Poster
2017 ASCO Annual Meeting
Association of delayed adjuvant therapy and overall survival in early stage endometrial cancer.
First Author: Leo Luo
Poster
2017 ASCO Quality Care Symposium
Adherence to ASTRO ‘Choosing Wisely’ recommendations for radiation therapy in low-risk endometrial cancer.
First Author: Joshua A. Roth
Poster
2014 ASCO Annual Meeting
A phase III trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate- or high-risk endometrial cancer. ENGOT-EN2-DGCG/EORTC 55102.
First Author: Mansoor Raza Mirza